Investigation into Potent Inflammation Inhibitors from Traditional Chinese Medicine

Chemical Biology and Drug Design

Volumn 78, Issue 4, 2011, Pages 679-688

  Chen, Kuan Chung ^a   Sun, Mao Feng ^a,b   Yang, Shun Chieh ^a   Chang, Su Sen ^a   Chen, Hsin Yi ^c   Tsai, Fuu Jen ^a,c   Chen, Calvin Yu Chian ^a,c,d,e  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d HARVARD MEDICAL SCHOOL   (United States)

^e CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

Author keywords

Anti inflammation; Docking; M PGES 1; Molecular dynamics; Quantitative structure activity relationship; Traditional Chinese medicine

Indexed keywords

ANTIINFLAMMATORY AGENT; AURANTIAMIDE ACETATE; CASTILLIFEROL; MF 63; SHANCIOL A; SHANCIOL B; UNCLASSIFIED DRUG;

ARTICLE; CHINESE MEDICINE; DRUG BINDING; DRUG POTENCY; HYDROGEN BOND; INFLAMMATION; MOLECULAR DOCKING; MOLECULAR INTERACTION; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUPPORT VECTOR MACHINE;

ANTI-INFLAMMATORY AGENTS; DRUG DISCOVERY; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MEDICINE, CHINESE TRADITIONAL; MICROSOMES; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT VECTOR MACHINES;

EID: 80052619174     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01202.x     Document Type: Article

References (42)

1. Ozben B., Erdogan O. (2008) The role of inflammation and allergy in acute coronary syndromes. Inflamm Allergy Drug Targets;7:136-144.
2. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis;30:1073-1081.
3. Rainsford K.D. (2007) Anti-inflammatory drugs in the 21st century. Subcell Biochem;42:3-27.
4. Koeberle A., Werz O. (2009) Inhibitors of the microsomal prostaglandin E-2 synthase-1 as alternative to non steroidal anti-inflammatory Drugs (NSAIDs) - A Critical Review. Curr Med Chem;16:4274-4296.
5. Zheng H., Wei D.Q., Zhang R., Wang C., Wei H. (2007) Screening for new agonists against Alzheimer's disease. Med Chem;3:488-493.
6. Chou K.C., Wei D.Q., Zhong W.Z. (2003) Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun;308:148-151.
7. Du Q.S., Huang R.B., Chou K.C. (2008) Review: recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr Protein Pept Sci;9:248-259.
8. Du Q.S., Huang R.B., Wei Y.T., Pang Z.W., Du L.Q., Chou K.C. (2009) Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design. J Comput Chem;30:295-304.
9. Liao Q.H., Gao Q.Z., Wei J., Chou K.C. (2011) Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on Epidermal Growth Factor Receptor (EGFR). Med Chem;7:24-31.
10. Wang J.F., Chou K.C. (2009) Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochem Biophys Res Commun;390:608-612.
11. Wang J.F., Chou K.C. (2010) Insights from studying the mutation-induced allostery in the M2 proton channel by molecular dynamics. Protein Eng Des Sel;23:663-666.
12. Chou K.C. (2004) Molecular therapeutic target for type-2 diabetes. J Proteome Res;3:1284-1288.
13. Chou K.C., Wei D.Q., Du Q.S., Sirois S., Zhong W.Z. (2006) Review: progress in computational approach to drug development against SARS. Curr Med Chem;13:3263-3270.
14. Chou K.C. (2004) Review: structural bioinformatics and its impact to biomedical science. Curr Med Chem;11:2105-2134.
15. Chen C.Y.C. (2009) Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping. J Taiwan Inst Chem Eng;40:155-161.
16. Chen C.Y.C. (2011) TCM Database@Taiwan: the World's largest traditional Chinese medicine database for drug screening in silico. PLoS ONE;6:e15939.
17. Li C.L., Chang T.T., Sun M.F., Chen H.Y., Tsai F.J., Fisher M., Chen C.Y.C., Lee C.L., Fang W.C., Wong Y.H. (2011) Structure-based and ligand-based drug design for microsomal prostaglandin E synthase-1 inhibitors. Mol Simulate;37:226-236.
18. Chang T.T., Sun M.F., Wong Y.H., Yang S.C., Chen K.C., Chen H.Y., Tsai F.J., Chen C.Y.C. (2011) Drug design for mPGES-1 from traditional Chinese medicine database: a screening, docking, QSAR, molecular dynamics, and pharmacophore mapping study. J Taiwan Inst Chem Eng;42:580-591.
19. Chen K.C., Chen C.Y.C. (2011) Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach. Soft Matter;7:4001-4008.
20. Chang T.T., Huang H.J., Lee K.J., Yu H.W., Chen H.Y., Tsai F.J., Sun M.F., Chen C.Y. (2010) Key features for designing phosphodiesterase-5 inhibitors. J Biomol Struct Dyn;28:309-322.
21. Huang H.J., Lee K.J., Yu H.W., Chen H.Y., Tsai F.J., Chen C.Y.C. (2010) A novel strategy for designing the selective PPAR agonist by the "Sum of Activity" model. J Biomol Struct Dyn;28:187-200.
22. Huang H.J., Lee K.J., Yu H.W., Chen C.Y., Hsu C.H., Chen H.Y., Tsai F.J., Chen C.Y.C. (2010) Structure-based and ligand-based drug design for HER 2 receptor. J Biomol Struct Dyn;28:23-37.
23. Chen C.Y., Chen C.Y.C. (2010) Insights into designing the dual-targeted HER2/HSP90 inhibitors. J Biomol Struct Dyn;29:21-31.
24. Chen C.Y.C. (2010) Virtual screening and drug design for PDE-5 receptor from traditional Chinese Medicine database. J Biomol Struct Dyn;27:627-640.
25. Chen C.Y.C. (2010) Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-targeted inhibitors. J Chinese Inst Chem Engs;41:143-149.
26. Li H., Sutter J., Hoffmann R. (2000) HypoGen: an automated system for generating predictive 3D pharmacophore models. In: Guner O.F., editor. HypoGen: An automated System for Generating Predictive 3D Pharmacophore Models. La Jolla, CA, USA: International University Line.
27. Cote B., Boulet L., Brideau C., Claveau D., Ethier D., Frenette R., Gagnon M. et al. (2007) Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett;17:6816-6820.
28. Giroux A., Boulet L., Brideau C., Chau A., Claveau D., Cote B., Ethier D. et al. (2009) Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett;19:5837-5841.
29. Riendeau D., Aspiotis R., Ethier D., Gareau Y., Grimm E.L., Guay J., Guiral S., Juteau H., Mancini J.A., Méthot N., Rubin J., Friesen R.W. (2005) Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett;15:3352-3355.
30. Wu T.Y., Juteau H., Ducharme Y., Friesen R.W., Guiral S., Dufresne L., Poirier H., Salem M., Riendeau D., Mancini J., Brideau C. (2010) Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1. Bioorg Med Chem Lett;20:6978-6982.
31. Koeberle A., Zettl H., Greiner C., Wurglics M., Schubert-Zsilavecz M., Werz O. (2008) Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Med Chem;51:8068-8076.
32. Wang J., Limburg D., Carter J., Mbalaviele G., Gierse J., Vazquez M. (2010) Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template. Bioorg Med Chem Lett;20:1604-1609.
33. Fan R.E., Chen P.H., Lin C.J. (2005) Working set selection using second order information for training support vector machines. J Mach Learn Res;6:1889-1918.
34. Saxena A.K., Prathipati P. (2003) Comparison of MLR, PLS and GA-MLR in QSAR analysis. SAR QSAR Environ Res;14:433-445.
35. Rogers D., Hopfinger A.J. (1994) Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem Inf Comput Sci;34:854.
36. Jegerschold C., Pawelzik S.C., Purhonen P., Bhakat P., Gheorghe K.R., Gyobu N., Mitsuoka K., Morgenstern R., Jakobsson P.J., Hebert H. (2008) Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc Natl Acad Sci USA;105:11110-11115.
37. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. (1983) CHARMM: a program for macromolecular energy minimization and dynamics calculations. J Comput Chem;4:187-217.
38. Venkatachalam C.M., Jiang X., Oldfield T., Waldman M. (2003) LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model;21:289-307.
39. Xu D., Rowland S.E., Clark P., Giroux A., Cote B., Guiral S., Salem M., Ducharme Y., Friesen R.W., Méthot N., Mancini J., Audoly L., Riendeau D. (2008) MF63 [2-(6-chloro-1H-phenanthro[9, 10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharm Exp Ther;326:754-763.
40. Accelerys Software Inc. (2009) Discovery studio modeling environment. Discovery Studio Modeling Environment. San Diego: Accelerys Software Inc.
41. Fletcher R. (1969) Optimization. Academic Press: New York and London.
42. Fletcher R., Reeves C.M. (1964) Function minimization by conjugate gradients. Comp J;7:149-154.